Access cutting-edge duchenne muscular dystrophy treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Chicago location
Access duchenne muscular dystrophy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related duchenne muscular dystrophy treatment provided free
Check if you qualify for this duchenne muscular dystrophy clinical trial in Chicago, IL
No-Cost Study Care
Local to Chicago
Convenient for IL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne. For additional information on how to participate (or be considered for the study), please follow this lin
Sponsor: REGENXBIO Inc.
Yes, this clinical trial (NCT05693142) has an active research site in Chicago, IL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for duchenne muscular dystrophy treatment options in Chicago, IL, this clinical trial (NCT05693142) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced duchenne muscular dystrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all duchenne muscular dystrophy clinical trials near you to find additional studies recruiting in your area.
See all ulcerative colitis clinical trials recruiting in Chicago — not just this study.
Browse Ulcerative Colitis Trials in Chicago →